'''Fluproquazone''' (trade name '''Tormosyl''', '''RF 46-790''' ) was a [[quinazolinone]] derivative with potent [[analgesic]], [[antipyretic]], and [[anti-inflammatory]] effects discovered by [[Novartis|Sandoz]].<ref>Haanaes HR, et al  RF 46-790 versus paracetamol: effect on post-operative pain. Int J Clin Pharmacol Ther Toxicol. 1986 Nov;24(11):598-601. {{PMID|3491794}}</ref><ref>Mohing W, Suckert R, Lataste X. Comparative study of fluproquazone in the management of post-operative pain. ''Arzneimittelforschung''. 1981;31(5a):918-20.</ref><ref>Wheatley D. Analgesic properties of fluproquazone. ''Rheumatology and Rehabilitation''. 1982 May;21(2):98-100.</ref><ref>Fankhauser S, Laube W, Marti HR, Schultheiss HR, Vogtlin J, von Graffenried B. Antipyretic activity of fluproquazone in man. ''Arzneimittelforschung''. 1981;31(5a):934-5.</ref>  It was withdrawn during development due to [[liver toxicity]].<ref>Lewis JH and Stine JG. Nonsteroidal Antiinflammatory Drugs and Leukotriene Receptor Antagonists, Ch 22 in Drug-induced Liver Disease (Third Edition). Eds Neil Kaplowitz and Laurie D. DeLeve. Elsevier Inc, 2013. {{ISBN|9780123878175}}</ref>{{rp|370}}<ref>Hyman J. Zimmerman. Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver. Lippincott Williams & Wilkins, 1999. {{ISBN|9780781719520}}</ref>{{rp|520}}
